european network for the study of adrenal tumors



This trial was a randomized, double-blind, phase II, international, multicenter study which is dedicated to determine the efficacy of Sunitinib on the progression-free survival at 12 months in patients with progressive malignant pheochromocytoma and paraganglioma.

Main inclusion criteria include diagnosis of malignant PPGL, based on imaging or biopsy evidence of metastases in liver, bones, lungs and or lymph nodes, combined with at least one of two further confirmatory diagnoses:

1. diagnosis of PPGL from histopathological review of resected or biopsied tissue or
2. in patients where tumor tissue is unavailable for formal pathological review, from combined biochemical and functional imaging evidence of PPGL (e.g., MIBG scintigraphy combined with consistently and highly elevated plasma or urine levels of metanephrines).
For more details see here.
A list of Study centers can be found





Baudin E, Goichot B, Berruti A, Hadoux J, Moalla S, Laboureau S, Nölting S, de la Fouchardière C, Kienitz T, Deutschbein T, Zovato S, Amar L, Haissaguerre M, Timmers H, Niccoli P, Faggiano A, Angokai M, Lamartina L, Luca F, Cosentini D, Hahner S, Beuschlein F, Attard M, Texier M, Fassnacht M; ENDOCAN-COMETE; ENSAT Networks. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial. Lancet. 2024 Mar 16;403(10431):1061-1070. PMID: 38402886.

  © ENS@T - European Network for the Study of Adrenal Tumors 2002 - 2012